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Abstract
Background: Pituitary tumor transforming gene (PTTG) is a novel oncogene that is expressed at
higher level in most of the tumors analyzed to date compared to normal tissues. Existence of a
relationship between PTTG levels and tumor angiogenesis and metastasis has been reported.
However, the mechanisms by which PTTG achieve these functions remain unknown. In the present
study, we investigated the effect of overexpression of PTTG on secretion and expression of
metastasis-related metalloproteinase-2 (MMP-2) in HEK293 cells, cell migration, invasion and
tubule formation.
Results: Transient or stable transfection of HEK293 cells with PTTG cDNA showed a significant
increase in secretion and expression of MMP-2 measured by zymography, reverse transcriptase
(RT/PCR), ELISA, and MMP-2 gene promoter activity. Furthermore, in our studies, we showed that
tumor developed in nude mice on injection of HEK293 cells that constitutively express PTTG
expressed high levels of both MMP-2 mRNA and protein, and MMP-2 activity. Conditioned medium
collected from the HEK293 cells overexpressing PTTG showed a significant increase in cell
migration, invasion and tubule formation of human umbilical vein endothelial cells (HUVEC).
Pretreatment of conditioned medium with MMP-2-specific antibody significantly decreased these
effects, suggesting that PTTG may contribute to tumor angiogenesis and metastasis via activation
of proteolysis and increase in invasion through modulation of MMP-2 activity and expression.
Conclusion: Our results provide novel information that PTTG contributes to cell migration,
invasion and angiogenesis by induction of MMP-2 secretion and expression. Furthermore, we
showed that tumors developed in nude mice on injection of HEK293 cells that constitutively
express PTTG induce expression of MMP-2 and significantly increase its functional activity,
suggesting a relationship between PTTG levels and MMP-2 which may play a critical role in
regulation of tumor growth, angiogenesis and metastasis. Blocking of function of PTTG or down
regulation of its expression in tumors may result in suppression of tumor growth and metastasis,
through the down regulation of MMP-2 expression and activity. To our knowledge, this study is the
first study demonstrating the modulation of MMP-2 expression and biological activity by PTTG.
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Primary tumor growth is restricted due to limited supply
of oxygen, nutrients, and growth factors. Tumor progres-
sion and invasion to distant organs depends on tumor
angiogenesis. To achieve angiogenesis various growth and
transforming genes are turned on to enable tumor pro-
gression [1]. Once angiogenesis is initiated, the tumor
expands exponentially and invades to local and distance
tissues. From a patient survival perspective point of view,
understanding the mechanisms of angiogenesis and
metastasis for the development of new therapeutics is a
critical step to treat tumors [2,3].
In this contest, many oncogenes have been reported to
play important roles in tumor angiogenesis and metasta-
sis. Recently, a novel oncogene, pituitary tumor trans-
forming gene (PTTG), also known as securin, has been
reported to play a vital role in tumor angiogenesis [4].
Using an mRNA differential technique, PTTG was origi-
nally cloned from a rat pituitary tumor [5], followed by
cloning of its homologue from humans [6-8]. The pre-
dominant cellular location of the PTTG protein is the
cytoplasm, although it is partially localized in the nucleus
[9]. Nuclear translocation of PTTG can be facilitated by
either interaction with PTTG binding factor (PBF) [10], or
by interaction with the mitogen-activating protein (MAP)
kinase cascade [11]. The level of PTTG expression is
increased in rapidly proliferating cells and is regulated in
a cell cycle-dependent manner [9,12]. PTTG expression is
low at the G1/S interphase, increases gradually during the
S phase, and peaks at the G2/M phase [12]. As the cells
enter into anaphase, PTTG is degraded and daughter cells
express very low amounts of PTTG. The degradation of
PTTG most likely occurs via ubiquitination since PTTG
contains a D box which is required for such proteolysis
[9].
Numerous studies have demonstrated that human PTTG
displays a distinct pattern of expression. In normal tissues,
PTTG expression is restricted, with high levels in testis,
and low levels in the thymus, colon, and small intestine
[6,13]. In contrast, PTTG is highly expressed in a variety of
human primary tumors as well as tumor cell lines includ-
ing tumor of the ovary, lung, testis, kidney, colon, thyroid,
pituitary, liver, adrenal, breast, prostate, melanoma,
leukemia, and lymphoma [6-9,12-19], suggesting that
PTTG may be involved in tumorigenesis. Furthermore,
increase in expression levels of PTTG have been predicted
to correlate with increased tumor invasiveness in human
pituitary tumors with hormone overproduction [16], and
with the degree of malignancy, pathogenesis and/or pro-
gression of colorectal and thyroid tumors [14,20]. PTTG
has been identified as one of eight signature genes that is
associated with tumor metastasis andis up regulated in
human primary solid tumors [15]. A relationship between
the survival rate and level of expression of PTTG in
esophageal cancer has been reported [21].
We and others have shown that overexpression of human
PTTG in mouse fibroblasts (NIH3T3) and human embry-
onic kidney (HEK293) cells increases cell proliferation,
induces cellular transformation in vitro and promotes
tumor formation in nude mice [5,6,22]. Currently, the
precise mechanism by which PTTG causes cell transforma-
tion remains unclear. Data from our laboratory and others
suggest that PTTG may act through basic growth factor
(bFGF) [22,23], vascular endothelial growth factor
(VEGF) [4,22], and/or interleukin-8 (IL-8) [22]. Addi-
tional mechanism by which PTTG may induce its onco-
genic function is indicated by findings that implicates its
role in sister chromatid separation during cell division
[24]. PTTG, by virtue of its function as a human securin,
ensures that there is no premature separation of sister
chromatids. Mice lacking PTTG show aberrant cell cycle
progression, premature centromere division, and prob-
lems with chromosomal stability, as well as tissue specific
phenotypes, such as testicular and splenic hypoplasia and
thymic hyperplasia[25]. In addition, PTTG null mice
exhibit impaired proliferation of pancreatic beta cells and
develop type I diabetes during late adulthood [26]. Fur-
thermore, crossbreeding of PTTG (-/-) mice with Rb (+/-)
mice showed significant reduction in pituitary tumor
development compared to PTTG (+/+)/Rb (+/-) mice;
incidence of pituitary development decreased from 80%
in PTTG (+/+)/Rb (+/-) animals to 30% in PTTG (-/-)/Rb
(+/-) animals [27]. On the other hand, transgenic animals
that express PTTG under the control of the αGSU pro-
moter showed enlarged pituitary and hyperplasia of pros-
tate [28]. Taken together, these data strongly suggest an
important role of PTTG in cell proliferation and tumori-
genesis.
Local invasive growth is a key feature of primary malig-
nant tumor. A correlation between the level of expression
of PTTG and invasiveness and degree of malignancy in
pituitary and colorectoral tumors has been reported [14].
However, the specific mechanisms by which PTTG facili-
tates invasive behavior remain unknown. It is known that
interactions between cancer cells and surrounding normal
cells and the extra-cellular matrix (ECM) are the key
events in tumor cell invasion [29,30]. For successful inva-
sion and to spread tumor cells through the surrounding
normal tissue, tumor cells must degrade multiple ele-
ments of the ECM, including fibronectin, laminin, and
type IV collagen [31,32]. Metalloproteinases (MMPs) are
potent proteolytic enzymes known to play key roles in
degradation of basement membranes and extracellular
matrix required for tumor cells to invade and metastasize.
The MMP family contains 24 members, of which MMP-2
(gelatinase A, 72-kDa type IV collagenase) and gelatinasePage 2 of 13
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eral cancers including breast cancer, colon cancer, skin
cancer and lung cancer [33-37] and their expression has
been correlated with local invasion by the tumor, lymph
node metastasis and survival rate [31-34,38,39]. Both
MMP-2 and MMP-9 cleave the type IV collagen and gela-
tin, which are the principal structural components of the
basement membrane (40). Since, PTTG is over-expressed
in most of tumors and its role in angiogenesis and metas-
tasis has been reported [14,15,20], we hypothesize that
some of the functions of PTTG may be mediated through
the regulation of expression of MMP-2 metalloproteinase
and modulation of its biological activity. In the present
study, we show that overexpression of PTTG in HEK293
cells results in up-regulation of secretion and expression
of MMP-2, but not MMP-9, resulting in increased cell
migration and invasion.
Results
PTTG increases the expression and activity of MMP-2 in-
vitro
Levels of both PTTG and MMP-2 are reported to correlate
with the angiogenesis and metastasis of tumor[15,35-38],
suggesting for a existence of relationship between PTTG
and MMP-2. To examine this possibility, we examine the
secretion and expression of MMP-2 in HEK293 cells tran-
siently or stably transfected with PTTG cDNA. As shown in
Fig. 1, HEK293 cells showed very low level of expression
of PTTG protein; however, transient transfection of these
cells with PTTG cDNA resulted in a significant increase in
expression of PTTG protein. Similar results were obtained
when HEK293 cells were stably transfected with PTTG
cDNA (results not shown). To examine whether PTTG
modulate the secretion of MMP-2 and MMP-9 from
HEK293 cells, we determined the MMP-2 and MMP-9 lev-
els in the conditioned medium by zymography. As shown
in Fig. 2A and 2C, transfection of HEK293 cells with PTTG
cDNA resulted in enhanced secretion of MMP-2 (~2-3-
fold) but not MMP-9 secretion (results not shown). These
results were further confirmed by ELISA, which showed
~5-fold increase in MMP-2 levels in CM collected from
HEK293 cells compared to CM collected from cells trans-
fected with pcDNA3.1 vector (Fig. 2C). Furthermore,
PTTG was found to increase the levels of both forms of
MMP-2 (active 62 kDa; and latent 72 kDa) (Fig. 2A and
2B). Addition of MMP-2-specific antibody to the condi-
tioned medium significantly decreased the activity of
MMP-2 (digestion of fluorescence collagenase substrate)
(Fig. 2D).
Increase in secretion of MMP-2 in CM by PTTG could be
result of increase in translation of MMP-2 protein from
MMP-2 mRNA or induction of secretion from stored vesi-
cles. To elucidate whether PTTG-induced MMP-2 secre-
tion was transcriptionally controlled, mRNA expression
levels of MPP-2 were examined by semi-quantitative RT/
PCR. Transfection of HEK293 cells with PTTG cDNA
resulted in a significant up-regulation of MMP-2 mRNA
compared to cells transfected with pcDNA3.1 vector (Fig.
3A and 3B), suggesting that enhanced MMP-2 secretion by
PTTG may be regulated at the transcriptional level. Further
to confirm that increase in MMP-2 mRNA levels were in
fact due to change in transcriptional activity of MMP-2
gene and not due to change in degradation or stability of
MMP-2 mRNA; we determined MMP-2 gene promoter
activity. As shown in Fig. 3C, our data demonstrated a sig-
nificant (~11-fold) increase in MMP-2 gene promoter
activity in cells transfected with PPTG cDNA compared to
cells transfected with pcDNA3.1 vector. Collectively, our
data suggest that PTTG increases MMP-2 secretion and
expression in HEK293 cells, and such increase by PTTG at
least in part is due to activation of MMP-2 gene transcrip-
tion.
Western blot analysis of PTTGFigure 1
Western blot analysis of PTTG. A: HEK293 cells were tran-
siently transfected with PTTG cDNA or pcDNA3.1 vector. 
After 48 h of transfection, cell lysates were prepared and 
used for Western blot analysis using the PTTG-specific 
antiserum. The blot was stripped and used for β-actin to 
examine equal loading of proteins. B: Graphical representa-
tion of Data shown in A. The immuno-reactive bands were 
scanned with densitometer, quantitated and normalized with 
β-actin. The data shown represent mean ± SEM of three 
independent experiments. ** = p < 0.05.
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To determine the role of PTTG on invasion and migration
of tumor cells through MMP-2, we used stably transfected
HEK293 cells. HUVEC suspended in serum free medium
were transferred to upper chamber of Boyden wells and
CM collected from HEK293 cells constitutively expressing
PTTG or pcDNA3.1 vector transfected cells was added to
the lower chamber as described in Materials and Methods.
Cells showed higher invasive index when CM from
HEK293 cells constitutively expressing PTTG was used
compared to CM from HEK293 cells stably transfected
with vector (Fig. 4). Such increase in cell invasion was
completely blocked by addition of MMP-2-specific anti-
body (2 µg/ml) to the medium but not by adding equal
MMP-2 secretion and expressionFigure 2
MMP-2 secretion and expression. A: Zymography analysis. Conditioned medium from HEK293 cells transiently or stably trans-
fected with PTTG cDNA or pcDNA3.1 vector was collected. MMP-2 and MMP-9 levels in the medium were determined by 
gelatin zymography. Both active (68 kDa) and latent (72 kDa) forms of MMP-2 are shown. B: Graphical representation of the 
data shown in A. Data represents mean ± SEM from three independent experiments. C: ELISA assay. Levels of MMP-2 and 
MMP-9 (ng/ml) in conditioned medium collected from HEK293 cells transfected with PTTG cDNA or pcDNA3.1 vector. Data 
represent mean ± SEM from three independent experiments. ** = p < 0.05. D: Measurement of MMP-2 functional activity using 
Direct Quenching (DQ) fluorescence conjugate collagenase analysis. DQ assay was performed as described in materials and 
methods. Activity of collagenase was approximately 2.5 fold higher in CM from HEK293 cells transfected with PTTG cDNA as 
compared to CM collected from cells transfected with pcDNA3.1 vector. Addition of MMP-2 blocking antibody (MMP2BA) 
completely blocked the collagenase activity. Data represent the mean ± SEM of three independent experiments performed in 
triplicate. ** = p < 0.05.Page 4 of 13
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invasion of cells was due to increased MMP-2 secretion
from HEK293 cells as a result of overexpression of PTTG.
PTTG increases the migration of HUVEC in vitro
To determine the effect of PTTG on cell migration, we per-
formed wound migration assays in 35 mm culture plates.
HUVEC cells were plated in 35 mm dishes and wound was
created as described in Materials and Methods. Cells were
incubated for 48 h in CM collected from HEK293 cells sta-
bly transfected with PTTG cDNA or pcDNA3.1 vector. Cell
migration was quantified by counting the number of cells
that migrated into the wounded area with a microscope
fitted with an eyepiece marked grid (1 mm2). As shown in
Fig. 5, there was a 95% increase in cell number migrated
into wounded area when CM collected from PTTG cDNA
transfected cells was used compared the CM collected
from cells transfected with pcDNA3.1 vector. Addition of
MMP-2-specific antibody to CM collected from HEK293
cells transfected with PTTG cDNA resulted a significant
Expression of MMP-2Figure 3
Expression of MMP-2. A: Semi quantitative RT/PCR analysis of MMP-2 mRNA in HEK293 cells transfected with PTTG CDNA 
or pcDNA3.1 vector. GAPDH was used as an internal control. B: PCR products shown in A were scanned and quantitated. 
MMP-2 expression was increased by ~22 fold in HEK293 cells transfected with PTTG cDNA compared to cells transfected 
with pcDNA3.1. C: Measurement of MMP-2 gene promoter activity. HEK293 cells were co-transfected with MMP-2 gene pro-
moter and PTTG cDNA or pcDNA3.1 vector. MMP-2 promoter gene promoter activity was measured by assaying luciferase 
activity. The data shown represent fold change of MMP-2 promoter activity in HEK293 cells when co-transfected with pGL2-
MMP-2 and PTTG cDNA compared to cells co-transfected with pGL2-MMP-2 and pcDNA3.1 vector. Values were normalized 
with renila luciferase activity used as an internal control and represent as mean ± SEM of three independent experiments per-
formed in triplicate. ** = p < 0.05.Page 5 of 13
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control mouse IgG showed no inhibitory effect, suggest-
ing an important role of MMP-2 in cell migration.
PTTG increases tubule formation and growth in 3D 
Matrigel matrix
MMP-2 is known to play an important role in the proteol-
ysis of ECM which allows endothelial cells to migrate
towards the angiogenic stimuli to form new blood vessels
to nurture tumor cells to grow. To determine if PTTG plays
a role in regulating MMP-2 function in such process, we
suspended HUVEC in CM collected from HEK293 cells
stably transfected with PTTG cDNA or pcDNA3.1 vector
and mixed with Matrigel matrix and assayed for the tubule
formation as described in materials and methods. As
shown in Fig. 6, cells suspended in CM collected from
HEK293 cells transfected with PTTG cDNA formed well
defined tubules, whereas cells suspended in CM collected
from HEK293 cells transfected with pcDNA3.1 vector did
not form tubules or formed undefined and irregular
tubules. Again addition of MMP-2 blocking antibody to
the CM collected from HEK293 cells with PTTG cDNA
completely abrogated tubule formation. On the other
hand addition of control mouse IgG to the CM was inef-
fective, suggesting that increased in MMP-2 secretion in
CM is due to overexpression of PTTG in HEK293 cells is
essential for tubule formation.
PTTG increases the secretion and expression of MMP-2 in 
vivo
As reported above, increase in PTTG expression activates
secretion and expression of MMP-2 in vitro, we were inter-
Cell invasion assayFigure 4
Cell invasion assay. HUVEC were transferred to upper chamber. CM collected from HEK293 cells transfected with PTTG 
cDNA or pcDNA3.1 vector was transferred to the lower chamber. Cell invasion index was calculated as described in Meth-
ods. CM was pre-incubated with MMP-2-specific antibody or control mouse IgG. B: Graphical representation of the data 
shown in A. Data represent mean ± SEM of three independent experiments performed in triplicate. ** = p < 0.05.Page 6 of 13
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vivo. To test it, we collected the tumors developed in nude
mice on injection of HEK293 cells constitutively express-
ing PTTG as described previously [22]. Analysis of tumors
for MMP-2 secretion, expression and MMP-2 functional
activity revealed a significant increase in secretion of
MMP-2 in tumors (measured by zymography), MMP-2
mRNA levels (measured by semi-quantitative RT/PCR)
and MMP-2 functional activity (measured by DQ fluores-
cence substrate activity) (Fig. 7) compared to other tissues
collected from the same animals. HEK293 cells trans-
fected with pcDNA3.1 vector or untransfected HEK293
cells did not develop tumors or developed very small
tumors [22], therefore were not available for comparative
analysis.
Discussion
Pituitary tumor transforming gene (PTTG) is a potent
oncogene. It is expressed at high levels in almost all the
tumors analyzed to date. Its oncogenic potential was dem-
onstrated by its overexpression in mouse fibroblast
NIH3T3 cells and human embryonic kidney HEK293
cells, which showed increased cell proliferation, colony
formation on soft agar and tumor formation in nude mice
[5,6,13,22]. High levels of PTTG expression have been
reported to correlate with highly aggressive and metastatic
tumors [15,41], and to regulate the expression of many
growth and angiogenic factors including bFGF, VEGF and
IL-8 [4,22,23,41]. However, the mechanisms by which
PTTG mediate its angiogenic and metastatic effects remain
unclear. Metalloproteinases are central to the ability of
cancer cells that play important role in tumor angiogen-
esis and metastasis by regulating the digestion of extracel-
lular matrix (ECM) to make way for tumor cells to move
and invade. It is well recognized that MMPs are also
involved in the expression and activation of various
chemokine, growth factors and their receptors [43]
required for biological and pathological processes includ-
Cell migrationFigure 5
Cell migration. Medium from HEK293 cells transfected with PTTG cDNA or pcDNA3.1 was used for HUVEC cells plated in 
35 mm dishes. A: Wound assay showing the migration of cells in wounded area. B: Graphical representation of data shown in 
A. A significant increase in HUVEC migration was observed when CM from HEK293 cells transfected with PTTG cDNA was 
used compared to CM from cell transfected with pcDNA3.1 vector. Addition of MMP-2-specific antibody significantly 
decreased the cell migration, whereas addition of control mouse IgG to CM was ineffective. Data shown represent mean ± 
SEM from three independent experiments performed in triplicate. ** = p < 0.05.Page 7 of 13
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MMPs are involved in the degradation of the surrounding
matrix, but MMP-2 has been at the forefront in tumor
invasion, angiogenesis, and metastases. Tumor and stro-
mal cells express high levels of MMP-2, which allows the
cells to invade and metastasize [29,30]. Importance of
MMP-2 in tumor progression and angiogenesis was inves-
tigated by Itoh et al. [46] who using MMP-2 deficient mice
showed reduced tumor burden and angiogenesis in these
mice. On the other hand Kato et al. [47] reported
decreased in the bFGF-induced corneal neovasculariza-
tion in MMP-2 deficient mice accompanied by reduction
in vascular endothelial cell migration and tubules forma-
tion.
Based on this information, we hypothesize that there
exists a relationship between PTTG and MMP-2 and some
of the oncogenic functions of PTTG may be mediated
through the modulation of expression and activity of
MMP-2. In our studies, we clearly showed that overexpres-
sion of PTTG in HEK293 cells resulted in a significant
increase in secretion of MMP-2 (Fig. 2) in the medium
and its mRNA levels in cells expressing PTTG compared to
cells transfected with pcDNA3.1 vector (Fig. 3). Such
increase in expression of MMP-2 by PTTG was found to be
at least in part through the regulation of MMP-2 gene tran-
scription.
Increase in MMP-2 levels showed increase in cell migra-
tion, invasion and tubule formation of HUVEC when
exposed to CM collected from cells transfected with PTTG
cDNA. Such effects of MMP-2 were completely blocked
when MMP-2-specific antibody were included in the
medium, specifically confirming the effects of MMP-2 in
cell migration, invasion and angiogenesis (Figs. 4, 5, 6).
PTTG is know to increase tumor angiogenesis and its rela-
tionship with tumor metastasis has been reported [4,15].
Our results clearly demonstrate that PTTG increases the
secretion and expression of MMP-2 which in turn regu-
lates cell migration, invasion and tubule formation in
vitro. Therefore, it is plausible that PTTG may serve as one
of the major regulators of MMP-2 and some of the onco-
genic effects of PTTG are being mediated through the reg-
ulation of expression of MMP-2.
Membrane type-1 (MT1) MMP specifically activates the
pro-gelatinase, MMP-2 on tumor cell surface in vitro and
binds with tissue inhibitor of matrixproteinases (TIMPs),
hence, controlling MMP-2 activity [48]. The delicate bal-
ance between MMP and TIMP levels ultimately deter-
mines the functions of MMP by protein degradation in
vitro [48]. Most of the MMP expression induced by acti-
vated MMP accompanies increased expression of one of
the TIMPs as a part of defense mechanism. TIMP2 protein
inhibits the activation of proMMP2 by forming a stable
complex with activated MT1-MMP, whereas low concen-
tration of TIMP2 can form a tertiary complex with MT1-
MMP and proMMP2 to eventually activate MMP2. Thus,
MT1-MMP combines with TIMP2 and influences the acti-
vation state of MMP2. In our studies we observed a signif-
Tubule formation assay: HUVEC cells were grown in Matrigel matrix mixed with CM collected from HEK293 cells transfected with PTTG cDNA (PTTG) or pcDNA3Fig r  6
Tubule formation assay: HUVEC cells were grown in Matrigel matrix mixed with CM collected from HEK293 cells transfected 
with PTTG cDNA (PTTG) or pcDNA3.1 vector (pcDNA). MMP-2-specific antibody was added to CM collected from HEK293 
transfected with PTTG cDNA (MMP2-BA) or control mouse IgG (IgG).Page 8 of 13
(page number not for citation purposes)
Molecular Cancer 2006, 5:61 http://www.molecular-cancer.com/content/5/1/61
Page 9 of 13
(page number not for citation purposes)
Expression of PTTG and MMP-2 in tumors and normal tissuesFigure 7
Expression of PTTG and MMP-2 in tumors and normal tissues. Tumors and other tissues were collected from nu/nu mice that 
developed tumors on injection of HEK293 cells constitutively expressing PTTG. A: Zymography analysis of tumor and normal 
tissues lysates. B: Semi-quantitative RT/PCR analysis of PTTG and MMP-2 expression using specific primers for PTTG and 
MMP-2 genes. GAPDH was used as an internal control. C: MMP-2 functional in situ fluorescence collagenase activity assay. The 
data shown are representative of three independent experiments.
Molecular Cancer 2006, 5:61 http://www.molecular-cancer.com/content/5/1/61icant increase in levels of MT1-MMP mRNA in HEK293
cells when transfected with PTTG cDNA (data not shown),
suggesting regulation of expression of both MMP-2 and
MT1-MMP by PTTG to achieve the required activation of
MMP-2 to mediate its tumorigenic function. In our stud-
ies, we also demonstrated that PTTG not only regulates
the expression of MMP-2 in vitro but it does regulate
MMP-2 expression and function in vivo (Fig. 7), however,
it remains unclear if blocking of MMP-2 activity in vivo
will inhibit angiogenesis and tumor development as result
of overexpression of PTTG in tumors
Methods
Cell culture
Human embryonic kidney cells (HEK293) and Human
umbilical vein endothelial cells (HUVEC) were obtained
form American Type Culture Collection (ATCC) (Manas-
sas, VA) and were maintained at 37°C in an atmosphere
of 5% CO2 in humidified air. HEK293 cells were cultured
in DMEM (Invitrogen, Carlsbad, CA) supplemented with
penicillin/streptomycin (100 IU/ml and 100 µg/ml) and
10% fetal bovine serum (FCS) (Hyclone, Atlanta, GA).
HUVEC cells were cultured in ECM medium (Clonetics,
Walkersville, MD) supplemented with Bullet Kit (EGM-
2). The cell lines were subcultured on routine basis every
3–4 days. The MMP-2 blocking antibody (MMP2BA) was
obtained from Chemicon (Temecula, CA). Porcine gelatin
and clostridium collagenases were from Sigma Chemical
Co. (St. Louis, MO). DQ collagen fluorescein conjugate
was purchased from Molecular Probes (Carlsbad, CA).
Transfection and collection of conditioned medium (CM)
For transient transfection, HEK293 cells were plated into
six well plates approximately 24 h prior to transfection.
Cells were transfected in serum-free medium using 1 µg of
plasmid DNA and 3 µl of transfectin (BioRad, Hercules,
CA) according to the manufacture's instructions. After 18
h of transfection, medium was replaced with serum-free
medium (DMEM) (Invitrogen) ± MMP-2 blocking anti-
body 2 µg/ml. After 48 h, conditioned medium (CM) was
collected, centrifuged and stored at -80°C. Tissue lysates
and stable clones of HEK293 cells transfected with
pcDNA3.1 or PTTG cDNA were generated as describe pre-
viously [22].
Western blot analysis
For western blot analysis, cells were lysed with lysis buffer
(20 mM Tris HCl pH7.5, 1 mM EDTA, 0.1% Nonidet P-
40, 1 mM PMSF, and 1µg/ml each of pepstatin, leupeptin
and aprotinin). Protein concentration for each sample
was determined by Bradford method (Bio-Rad). An equal
amount of protein (40 µg) from each sample was sub-
jected to SDS-PAGE as described previously [49]. The pro-
teins were blotted onto nitrocellulose membrane and was
incubated with PTTG antiserum diluted at 1:1,500 at
room temperature for 1 h, followed by incubation with
goat anti-rabbit HRP-conjugated PTTG secondary anti-
body for 45 min. Immuno-reactive proteins were detected
by using enhanced chemiluminescent (ECL) assay system
from GE Healthcare Biosciences, Corp. (Piscataway, NJ).
Measurement of secretion of MMP-2 and MMP-9 in 
conditioned medium
A: ELISA assays
To determine the effect of PTTG on secretion of MMP-2
and MMP-9 in tissue culture medium, we measured the
levels of MMP-2 and MMP-9 in CM collected from
HEK293 cells transfected with PTTG cDNA using com-
mercially available ELISA kits from BD Biosciences (Min-
neapolis, MN) and zymography. Briefly, HEK293 cells
were transiently transfected with pcDNA3.1 or pcDNA3.1-
PTTG cDNA using transfectin transfection reagent (Bio-
Rad) as described above. After 24 h of transfection, the
medium was replaced with serum free DMEM medium.
Twenty-four h later, the medium was collected, centri-
fuged and concentrated by 5-fold (1.0 ml to 200 µl) using
a speedVac system (Savant, Holbrook, NY). Protein was
determined by the Bradford method [50]. Levels of MMP-
2 and MMP-9 were determined by ELISA assays and
zymography. ELISA assays were performed according to
instructions from the supplier. All measurements were
normalized to protein concentration and performed in
triplicate.
B: Zymography
Gelatin zymography analysis was carried out as described
by Heussen et al. [51]. Briefly 20 µg of CM protein from
each sample was loaded on polyacrlyamide gel containing
0.1% gelatin (Sigma Co., St. Louis, MO). Electrophoresis
was performed under non-reducing conditions at 20 mA
for 3 h at room temperature. The gel was washed twice for
30 min each in 2.5% Triton X-100 to remove SDS, incu-
bated in substrate buffer (50 mM Tris-HCl, 5 mM CaCl2,
0.01% NaN3, pH 7.6) for 24 h at 37°C. Gel was stained
with 0.5% Coomassie brilliant blue G-250 (Pierce Rock-
ford, IL) for 30 min at room temperature, and destained
(30% ethanol, 10% acetic acid, 60% water). The presence
of MMP-2 was indicated by an unstained proteolytic zone
of substrate at position of 72 kDa (MMP-2 active form)
and 68 kDa (MMP-2 latent form) compared to maker
applied on the same gel). The gel was scanned using NIH
image software, and data are presented as fold change
compared to control i.e. pcDNA transfected conditioned
medium.
Measurement of MMP-2 activity
To determine change in MMP-2 activity 20 µl of collagen
fluorescent substrate was reconstituted in PBS, mixed with
80 µl of reaction buffer (0.5 M Tris-HCl, 1.5 M NaCl, 50
mM CaCl2, 2 mM NaN3, pH 7.6) and added to the fluo-Page 10 of 13
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without MMP-2 blocking antibody collected from
HEK293 cells transfected with PTTG cDNA or pcDNA3.1
vector was added to each well. Clostridium collagenase
was serially diluted and used as a positive control and
reaction buffer was used as a negative control. The plate
was incubated at room temperature for 1 h. After incuba-
tion, the intensity of the digested product from DQ colla-
gen was measured at excitation 495 nm and emission at
515 nm in the fluorescence microplate reader. The fold
change was calculated by dividing the mean of fluores-
cence values of CM collected from cells transfected with
PTTG cDNA by the mean value of fluorescence of condi-
tioned medium collected from cells transfected with
pcDNA3.1 vector.
Measurement of MMP-2 activity in tumors
MMP-2 activity and expression in tumors and normal tis-
sues collected from nu/nu mice as describe previously
[22]. Briefly, nu/nu mice were injected subcuatneously
with HEK293 cells constitutively expressing PTTG. After
four weeks of injection when large tumors were devel-
oped, animals were scarified. Tumors and other tissues
(lung, heart, kidney and liver) from the same animal were
collected and stored at -80°C for further use. For MMP-2
activity and expression, DQ collagen substrate (1 mg/ml)
was mixed with reaction buffer (0.5 M Tris-HCl, 1.5 M
NaCl, 50 mM CaCl2, 2 mM NaN3, pH 7.6) containing
0.8% low melt agarose (Invitrogen) at a ratio of 1:1
according to Gailis et al. [52]. After melting agarose mix-
ture at 60°C, the mixture was applied on the frozen tissue
sections on glass slides and allowed to solidify at room
temperature. Slides were incubated in a humidified cham-
ber with a few drops of reaction buffer on each slide for 5–
7 days. Assessment of degradation of substrate was exam-
ined with an Olympus fluorescence microscope and pho-
tographed with a KODAK DC290 digital camera.
Determination of MMP-2 mRNA levels using RT/PCR
Total RNA was isolated from transfected HEK293 cells in
log phase or tumor and normal tissues using Trizol rea-
gent (Invitrogen) as described previously [6]. First strand
cDNA was synthesized using iScript RT-PCR kit (Bio-Rad)
and subsequently used for PCR amplification using the
specific primers for MMP-2, and GAPDH [22,53] using
Taq DNA polymerase (Takra). PCR conditions were 95°C
for 5 min followed by 95°C for 1 min, 54°C for 30 sec
and 72°C for 30 sec for 30 cycles with a final extension for
5 min at 72°C. Ten µl of PCR product from each sample
was subjected to electrophoresis on a 1.5% agarose gel.
Gel was stained with ethidium bromide and destained.
In vitro invasion assay
In vitro cellular invasion was assayed by determining the
ability of cells to invade a synthetic basement membrane
(Matrigel, BD Bioscience). Briefly, polycarbonate filters (8
µm pore size) were coated with Matrigel at a concentra-
tion of 1 µg/ml and placed in modified Boyden chamber.
Conditioned medium was collected from HEK293 cells
stably transfected with PTTG cDNA or pcDNA3.1 vector.
HUVEC cells were suspended in serum free medium. A
total of 2 × 105 cells were transferred to the top chamber.
Conditioned medium with and without MMP-2-antibody
was added to the lower chamber. The cells were incubated
at 37°C and allowed to invade through Matrigel barrier
for 22 h. Following incubation non-migrated cells in the
upper chamber were removed with a clean cotton swab.
Migrated cells through the Matrigel were stained with
Eosin and Giemsa. Cells were counted and invasion index
was calculated by dividing the percent of cells that
migrated through the Matrigel by the percent of cells that
moved through the pores of uncoated membrane.
Wound migration assay
The wound migration assay was performed as described
by Leavesley et al. [54] with slight modifications. HUVEC
were grown in 35 mm culture dishes to 80% confluencey.
A wound was formed using a 200 µl pipette tip to clear the
cell monolayer, and the boundary of the wound was
marked. Cells were then washed three times with PBS. The
CM was applied in different combinations with and with-
out MMP-2 blocking antibody. Mouse IgG (Sigma) was
used as a control. Cells were incubated for 18–20 h at
37°C under 5% CO2 atmosphere. After incubation, cells
were fixed with methanol, stained with Giemsa stain
diluted 1:10 (Sigma Chemical Co.), and photographed.
Cell migration was measured by counting the number of
cells that migrated into the clear space using an Olympus
microscope at 40X fitted with an ocular grid. The values
represented are the mean of four different random fields.
The fold change was determined by dividing the mean
number of cells that moved from the wound edge to the
wounded area in experimental culture by cells that moved
from the wound edge in the control culture.
Tubule formation assay in 3D matrigel matrix
To determine the effect of PTTG on tubule formation
forty-eight well plates were coated with 20 µg/ml of
Matrigel (GF-reduced BD Bedford MA). HUVEC (2 × 103
cell/ml) were plated in the Matrigel matrix with CM with
or without MMP-2 blocking antibody. After 4 h, 100 µl of
Matrigel-CM (Matrigel + conditioned medium mixed at a
ratio of 1:2) was overlaid on cells. Cells were allowed to
differentiate into tubule as described by Bootle-Wilbra-
ham et al. [55]. After 3 days, tubule formation was
assessed by fixing the cells with methanol for 15 min, fol-
lowed by rinsing with PBS. Three random fields were
viewed in triplicate wells for each test condition under
high power Olympus (400X) microscope. Color images
were captured using Kodak DC290 digital camera linkedPage 11 of 13
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fication of tubule formation was carried out by counting
the number of tubule branched in the total area covered
by tubules in each field using image analysis software
Photoshop version 7. A numerical value was assigned to
each pattern according to the network of tubule forma-
tion. A numerical value of 0–1 was assigned when the cells
are well separated, 2–3 when cells begin to migrate and
align to form tubes, and 4–5 when capillary tubes or
closed polygons begin to form.
Measurement of MMP-2 gene promoter activity
To examine if PTTG activate the transcription of MMP-2
gene, we determine the MMP-2 gene promoter activity. A
human MMP-2 gene promoter sequence (1959 bp
upstream of the transcription start site) cloned into luci-
ferase reporter gene construct (pGL2) was obtained from
Dr. Etty Beneveniste, University of Alabama at Birming-
ham, AL [56]. HEK293 cells were co-transfected with five
hundred ng of the MMP-2 gene promoter construct or
pGL2 construct with 500 ng of pcDNA3.1 or PTTG cDNA
construct. Renilla-luciferase construct (pRenilla-Luc,
Promega) 100 ng was used as an internal control as
described above. After 48 h of transfection, cells were
washed with PBS and lysed with 500 µl of 1X cell lysis
buffer from Promega. Luciferase and renila luciferase
activities were measured using dual substrate system from
Promega in Zylux Femtometer FB12 luminometer. Luci-
ferase activity for each sample was normalized to renila
activity used as an internal control.
Statistical analysis
Statistical comparison of data was carried out by the Stu-
dent's t test (for single comparison) or by one-way
ANOVA (for multiple comparisons). Probability of p <
0.05 determined from the two-sided test was considered
significant. The statistical analysis was carried out by using
SPSS 10.0 software.
Conclusion
In summary, our results demonstrate that PTTG contrib-
utes to cell migration, invasion and angiogenesis by
induction of MMP-2 secretion and expression. Blocking of
MMP-2 function by using MMP-2-specific antibody
decreases the cell migration and invasion induced by
PTTG, suggesting for a existence of relationship between
PTTG levels and MMP-2 expression and activity. Our
results demonstrate that blocking or down regulation of
PTTG expression in tumors overexpressing PTTG may
result in suppression of tumor growth and metastasis,
through the down regulation of MMP-2 expression and
activity. Based on these results, we conclude that PTTG
may serve a potential molecular target for cancer treat-
ment.
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